Baird analyst David Rescott lowered the firm’s price target on Inspire Medical (INSP) to $50 from $63 and keeps a Neutral rating on the shares. The firm updated its model following better than expected Q1 results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded at BofA on cloudy path back to growth
- Inspire Medical downgraded to Neutral from Buy at BofA
- Inspire Medical downgraded to Neutral from Overweight at Piper Sandler
- Inspire Medical Cuts 2026 Outlook Amid Reimbursement Headwinds
- Inspire Medical cuts FY26 adjusted EPS view to 75c-$1.25 from $1.85-$2.35